Research
Molecular
Aberrant activation of SCD1 contributes to obesity, non-alcoholic fatty liver, diabetes, and cancer.
Targeting SCD1 may help in managing these metabolic diseases.
StrongSupportsmedium confidence
Aberrant transcriptional and epigenetic activation of SCD1...promoting the progression of obesity, non-alcoholic fatty liver, diabetes and cancer.
Why this rating
The abstract provides a clear link between SCD1 and multiple diseases.
Source
SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors
Qin Sun et al. · Biomedicine & Pharmacotherapy · 2023
DOI 10.1016/j.biopha.2023.115586
reviewCited 101×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →